Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea berichtet über Präsentation gepoolter Wirksamkeitsdaten für Derazantinib bei iCCA-Patienten mit Mutationen und Amplifikationen der FGFR2 Gene auf dem ESMO MAP Virtual Congress 2020

Basel, 12. Oktober 2020 Basilea Pharmaceutica AG (SIX: BSLN) berichtete heute, dass ihr Fibroblasten-Wachstumsfaktor Rezeptor (FGFR) Kinase-Inhibitor Derazantinib Antitumor-Aktivität bei Patienten...
October 12, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020

Basel, Switzerland, October 12, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) today reported that its fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, demonstrated antitumor efficacy...
October 07, 2020 08:00 ET | Source: Routemaster Capital Inc.

Routemaster Announces $2 Million Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Routemaster Capital Inc. (TSX-V: RM) (“Routemaster” or...
October 06, 2020 08:00 ET | Source: Routemaster Capital Inc.

Routemaster Capital Signs LOI to Acquire 49% Interest in DeFi Holdings Inc., a Company Pursuing Investments in the Decentralized Finance Market

TORONTO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Routemaster Capital Inc. ( the “Company” or “Routemaster”) (TSX: RM) is pleased to announce it has entered into a binding Letter of Intent (“LOI”) to...
October 01, 2020 09:00 ET | Source: Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. Signs Letter of Intent with Brujera Elixirs Inc. to Formulate 4 Innovative Adaptogenic Mushroom-Infused Beverage Products

VANCOUVER, British Columbia, Oct. 01, 2020 (GLOBE NEWSWIRE) -- PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) ("Primo Nutra" or the "Company") Further...
September 29, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea initiiert zielgerichtete, Biomarker-basierte Phase-2-Studie mit Lisavanbulin bei Patienten mit Hirntumoren

Basel, 29. September 2020 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie eine Phase-2- Erweiterungsstudie mit ihrem Tumor-Checkpoint-Controller Lisavanbulin initiiert hat. In dieser...
September 29, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain cancer

Basel, Switzerland, September 29, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated a phase 2 expansion study with its tumor checkpoint controller, lisavanbulin, in...
September 28, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea beginnt Phase-1/2-Studie FIDES-03 mit Derazantinib bei Patienten mit Magenkrebs

Basel, 28. September 2020 Basilea Pharmaceutica AG (SIX: BSLN) gab heute den Beginn der Phase-1/2-Studie FIDES-03 mit dem FGFR-Inhibitor Derazantinib bekannt. Die Multikohorten-Studie erprobt...
September 28, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer

Basel, Switzerland, September 28, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the phase 1/2 study, FIDES-03, with the FGFR inhibitor derazantinib. The...
September 24, 2020 09:00 ET | Source: Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. and Dan Duquette, Former MLB Executive, Sign Definitive Agreement to Capitalize on Primo Receiving an MDEL License from Health Canada and announces Stock Option Grant

VANCOUVER, British Columbia, Sept. 24, 2020 (GLOBE NEWSWIRE) -- PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) ("Primo" or the "Company") is pleased...